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Dorsal and ventral striatal dopamine D1 and D2 receptors
differentially modulate distinct phases of serial visual
reversal learning
Júlia Sala-Bayo1, Leanne Fiddian1, Simon R. O. Nilsson1, Mona E. Hervig1, Colin McKenzie1, Alexis Mareschi1, Maria Boulos1,
Peter Zhukovsky1, Janet Nicholson2, Jeffrey W. Dalley1,3, Johan Alsiö1 and Trevor W. Robbins 1
Impaired cognitive flexibility in visual reversal-learning tasks has been observed in a wide range of neurological and
neuropsychiatric disorders. Although both human and animal studies have implicated striatal D2-like and D1-like receptors (D2R;
D1R) in this form of flexibility, less is known about the contribution they make within distinct sub-regions of the striatum and the
different phases of visual reversal learning. The present study investigated the involvement of D2R and D1R during the early
(perseverative) phase of reversal learning as well as in the intermediate and late stages (new learning) after microinfusions of D2R
and D1R antagonists into the nucleus accumbens core and shell (NAcC; NAcS), the anterior and posterior dorsomedial striatum
(DMS) and the dorsolateral striatum (DLS) on a touchscreen visual serial reversal-learning task. Reversal learning was improved after
dopamine receptor blockade in the nucleus accumbens; the D1R antagonist, SCH23390, in the NAcS and the D2R antagonist,
raclopride, in the NAcC selectively reduced early, perseverative errors. In contrast, reversal learning was impaired by D2R
antagonism, but not D1R antagonism, in the dorsal striatum: raclopride increased errors in the intermediate phase after DMS
infusions, and increased errors across phases after DLS infusions. These findings indicate that D1R and D2R modulate different
stages of reversal learning through effects localised to different sub-regions of the striatum. Thus, deficits in behavioral flexibility
observed in disorders linked to dopamine perturbations may be attributable to specific D1R and D2R dysfunction in distinct striatal
sub-regions.
Neuropsychopharmacology (2020) 45:736–744; https://doi.org/10.1038/s41386-020-0612-4
INTRODUCTION
Cognitive flexibility, the ability to adapt behavior to changes in the
environment, is impaired in a wide range of neurological and
neuropsychiatric disorders, including schizophrenia [1], obsessive-
compulsive disorder (OCD) [2], Parkinson’s disease (PD) [3] and
substance use disorder [4]. Such cognitive dysfunction can be
evaluated in reversal-learning tasks. Converging evidence from
such tests implicates dopamine (DA) as an important modulator of
reversal learning. For instance, systemic blockade or agonism of
D2-like receptors (D2R) impairs reversal learning in vervet monkeys
and rats [5, 6], while D2R knockout mice show deficiencies in initial
visual discrimination and in reversal learning [7]. In contrast,
pharmacological activation of D1-like receptors (D1R) impaired
early phases of reversal learning [8], whereas D1R antagonism did
not alter reversal learning performance [5]. In healthy humans,
repeat variations in the dopamine transporter gene, DAT1, have
been linked to performance during the early, perseverative phase
of reversal learning, when prior beliefs about the stimulus-reward
outcomes still guide behavior, whereas accuracy during later
phases, when new learning takes place, showed no such link [9].
The main sub-regions of the dorsal striatum, namely the
caudate nucleus and the putamen in primates and the
dorsomedial and dorsolateral striatum in rodents (DMS; DLS),
have also been differentially linked to reversal learning. Recent
evidence suggests that pharmacological inactivation of the
putamen and caudate nucleus differentially affect serial visual
reversal learning in marmoset monkeys [10]. Furthermore, D2R
availability in these sub-regions of vervet monkeys is associated
with reversal learning performance [11]. Importantly, the DMS
appears strongly linked to the early, perseverative phase of
reversal, whereas the DLS becomes engaged during later stages
[12]. This is perhaps in line with the view that the DLS mediates
stimulus-response habits whereas the DMS—especially the ante-
rior over the posterior DMS (aDMS; pDMS; [13], but see [14])—is
more strongly associated with goal-directed actions [15]. Both
forms of control over instrumental behavior are likely necessary
for implementing a new strategy following contingency reversal,
specifically the ability to suppress prepotent, perhaps habitual,
responding to the previously rewarded (and now unrewarded)
stimulus, and flexibly learn to select, via goal-directed behavior,
the previously unrewarded (now rewarded) option [16].
In the ventral striatum, previous studies have shown that
increased dopaminergic tone in the nucleus accumbens (NAc), or
infusions of a D2R agonist (quinpirole) into this area impaired
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reversal learning in rats [17], whereas infusions of a D1R agonist
(SKF81297) disrupted set-shifting by increasing perseverative
behavior [17, 18]. Lesions of the NAc disrupted initial stimulus
discrimination and reversal learning [19, 20], including spatial, but
not visual, reversal learning in monkeys [21], and pharmacological
inactivation impaired probabilistic learning in rats [22]. However,
other studies report no effect of NAc interventions on such
flexibility [23, 24]. This discrepancy may be explained by the
heterogeneity of the NAc with the core and shell sub-regions
(NAcC; NAcS) contributing differentially to attention [25, 26] and
impulsivity-related behaviors [27–29], with these NAc sub-regions
often being suggested to play opposite roles in modulating
behavior. For instance, inactivation of the NAcS impaired
probabilistic reversal performance in rats, identifying a key role
for this nucleus in using probabilistic reward feedback to facilitate
discriminative learning and flexibility, whereas inactivation of the
NAcC, while not affecting performance accuracy did cause a
general slowing of approach toward the response levers [22].
Taken together, this evidence suggests a general pattern of
impaired reversal learning when DA activity is low in the dorsal
striatum and when the dopaminergic tone is elevated in the
ventral striatum. However, there is no clear evidence of the role of
D1R and D2R in different sub-regions of the striatum in visual
reversal learning or of their involvement in its different learning
phases.
We therefore sought to investigate whether D1R and D2R
differentially affect reversal learning both across different striatal
sub-regions, including DLS, aDMS, pDMS, NAcC and NAcS, and on
the different phases of reversal learning by exploring the
behavioral effects of local administration of a D2R antagonist
and a D1R antagonist using a recently established touchscreen
task for rats [30].
MATERIALS AND METHODS
Subjects
The subjects were 82 male Lister-Hooded rats (Charles River, UK)
initially housed in groups of up to 4 under humidity- and
temperature-controlled conditions and a 12:12-h light-dark cycle
(lights off at 0700 h). Following implantation of guide cannulae,
animals were singly housed. Rats were ≈300 g at the beginning of
training and were maintained at >85% of their free-feeding
weight by food restriction (19 g/day of Purina chow). Water was
provided ad libitum. The number of animals used for each
experiment is shown in Table 1. The work was carried out under a
UK Home Office Project license (PPL 70/7548) in accordance with
the UK Animals (Scientific Procedures) Act 1986 and local ethical
review at Cambridge University.
Experimental procedures
Surgeries and microinfusion procedures are described in the Sup-
plementary Materials and Methods.
Behavioral pre-training
All software was written by Dr. A. C. Mar [30]. Rats were initially
trained to touch the screens with daily sessions of 60min or 100
trials. Pre-training consisted of five stages with gradually increased
difficulty (Fig. 1b). Briefly, in stage 1, a large white horizontal square
‘start-box’ (15 × 9 cm) was presented in the bottom center of the
screen, and touching it was associated with reward (45mg sucrose
pellet; TestDiet 5UTL; Sandown Scientific, Middlesex, UK). The size
of the ‘start box’ decreased throughout the stages until measuring
3 × 4 cm in stage 3. Animals were moved to the next stage when
reaching 100 responses/rewards per session. In stage 4, touching
the white box was not reinforced but led to the presentation of a
visual stimulus (vertical or horizontal bars) with a pseudo-random
spatial placement, left or right. The same stimulus was not
displayed on the same side for more than three consecutive trials
to avoid side-biasing. Responding to the stimulus was reinforced,
whereas the blank side led to the illumination of the house-light
for a 5 s time-out (TO) period. After collecting the reward, there was
an inter-trial interval (ITI) of 5 s. In stage 5, the stimuli were
presented slightly higher to avoid accidental touches e.g. with the
tail. The criterion to move from stages 4 and 5 was reaching ≥80%
of correct responses per session.
Visual discrimination training
After the initial training stages, subjects were trained on a visual
two-choice discrimination task (Fig. 1). Touching the square ‘start-
box’ triggered the simultaneous presentation of two stimuli
(vertical and horizontal bars), determined pseudo-randomly on
either left or right side of the screen [30]. The start-box procedure
was used to ensure the central position of the animal before the
choice phase. Responses to one stimulus (CS+) were associated
with reward and collecting the reward initiated the next ITI. In
contrast, responses to the other stimulus (CS−) were not rewarded
and led to a house light-signaled TO. The response window after
stimulus presentation was set to 10 s. After this time, the trial was
considered as an omission and led to a new ITI. The session ended
after 250 trials, 150 rewards or 1 h, whichever came first. Criterion
for discrimination learning was set to 24 correct responses out of
30 consecutive trials. Once acquired within any session, rats were
given a retention session with the same reward contingencies to
ensure they had reliably acquired the visual discrimination.
Serial visual reversal learning
Following acquisition of visual discrimination, animals were
trained in serial visual reversal learning (Fig. 1c). After the
discrimination and retention sessions, contingencies reversed so
the previous CS+ was then CS− and vice versa. Rats were required
to respond to the new CS+ until reaching the discrimination
criterion (≥24/30 correct responses). After reaching criterion, an
extra retention session was run. Additional reversals were
performed until the rats were able to attain the criterion within
3 daily sessions. When this was met, rats underwent surgery prior
to testing. A retention session was run before each reversal and
after reaching the criterion (Fig. 1d), both in training and testing.
Data analysis
The main dependent variables were the number of errors and
trials to criterion (≥24/30 correct responses). Omissions, latencies
to respond and latencies to collect the reward were additionally
analyzed. Data from each reversal were collapsed over days. Trial
outcomes were classified in three different phases: early, mid or
late, depending on the performance over a running window of 30
consecutive trials [30, 31]. If animals had a significant bias
(binomial distribution probabilities) towards the previously
Table 1. Coordinates and group size for the different striatal sub-
regions and DA receptor antagonists, raclopride (D2R) and
SCH23390 (D1R).
Coordinates NAcC NAcS aDMS pDMS aDLS
Guide cannulas
AP +1.2 +1.6 +1.2 −0.4 +1.2
ML ±1.9 ±0.75 ±1.9 ±2.6 ±3.5
DV −1.9 −1.9 −1.9 −2.4 −2.4
Injectors
DV −6.9 −6.9 −4.4 −4.4 −4.4
n
Raclopride 22 10 15 15 11
SCH23390 13 9 15 10 5
AP and ML were measured from bregma and DV from dura
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positive stimulus (<11/30 correct responses), performance was
considered to belong to the early phase, in which animals
exhibited mainly perseverative responses. If their performance
instead showed a significant preference for the currently rewarded
stimulus (>19/30 correct responses) it was considered as the late
phase, in which animals moved closer to criterion for learning the
reversed contingency. Performance in-between these thresholds
was classified as intermediate or mid-phase, prior to acquisition of
the new learned association. Data from all trials after the rats had
reached the final learning criterion (≥24/30 correct responses)
were excluded from the analysis.
Statistical tests were performed with RStudio, version 1.2.1335
(RStudio, Inc). Errors were square-root transformed and latencies
log transformed to ensure normality. Data were then subjected to
Linear Mixed-Effects Model analysis with the lmer package in R.
The model contained three fixed factors (dose, phase, region) and
one factor (subject) modeled as a random slope to account for
individual differences between rats across phases (i.e. individual
learning curves). Significance was considered at α= 0.05. The
normality of residuals was confirmed with a quantile-quantile plot
(QQ plot) and model fitting was tested with a Chi-squared test.
When significant three-way interactions were found, further
analysis was performed by conducting separate multilevel models
on “dose” and “phase” for each region. In the absence of
significant three-way interactions, two-way Dose × Region inter-
actions were explored further. Analysis was followed by post hoc
Tukey’s corrected pairwise comparisons.
RESULTS
Histology
The ventral-most locations of injectors are included in each of the
data figures. Rats were excluded from the study if the injector
cannulas were positioned outside the target areas (n= 3 pDMS,
n= 5 DLS and n= 1 NAcC). Final group sizes with verified injector
positions for each of the drug groups and targeted coordinates
are shown in Table 1.
Effects of intra-striatal infusions of the D2R antagonist raclopride
and the D1R antagonist SCH23390
Across all behavioral variables we found no significant differences
between the aDMS and pDMS. We therefore combined these two
regions as ‘DMS’ for subsequent analysis. Separate data for each of
these regions are given in the Supplementary Material online.
Figures 2 and 3 indicate that whereas local infusions of the D2R
antagonist raclopride improved early stages of reversal learning
when administered into the NAcC, they impaired reversal when
given in the dorsal striatum, both in the DMS (mid-phase) and DLS
(across phases). In contrast, D1R antagonism in the NAcS
improved the early phase of reversal learning but did not affect
the number of errors when administered into the NAcC.
Analysis for both raclopride and SCH23390 treatments sub-
stantiated that the effect of drugs varied across regions and
phases of the reversal task. For the number of errors committed
we found a significant Dose × Phase × Region interaction after
both raclopride (F12, 479.990= 4.109, p= 0.005) and SCH23390
(F6, 191.999= 4.109, p < 0.001) treatment. This was matched by
significant Dose × Phase × Region interactions in number of
trials per phase after antagonists administration (Raclopride:
F12, 407.990= 5.300, p < 0.001; SCH23390 F6, 192.010= 3.280, p=
0.004). In addition, there was a significant Dose × Phase ×
Region interaction on omissions after SCH23390 microinfusions
(F6, 232.089= 11.512, p < 0.001), whereas no such effect was
detected for raclopride (ns). On latencies, we observed no three-
way interactions, but a number of Dose × Region interactions.
Thus, we found a significant Dose × Region interaction in latencies
Fig. 1 Schematic representation of the task. a Behavioral training and testing protocol. The rewarded stimulus is represented as a + and the
unrewarded stimulus as a −. Stimuli were vertical or horizontal bars and were counterbalanced as CS+ or CS− across rats. b Diagram of pre-
training stages, from 1 to 5. Stimulus presentation in stages 4 and 5 was preceded by the same starting box from stage 3. Only one of the two
stimuli appeared at any one time. Position (i.e. left/right) was pseudo-randomized. c Representation of the stimuli during visual discrimination
(VD) and reversal learning. Criterion was reached at a performance of ≥24/30 correct responses, which represents a performance at or above
80%. After criterion was met during both reversal learning and in two retention sessions, conditions changed again. d Flowchart of the testing
procedure and phases of reversal learning. Phases depended on performance within sessions. After reversal, during the early phase
performance was lower than 11 correct trials out of a set of 30 trials, as animals tended to perseverate on the previously CS+, now CS−. After
some trials, performance improved, and animals reached the so-called mid, intermediate or random phase, before reaching the late or
learning phase, in which they have learnt to approach the new CS+ (>19/30 correct responses) [30, 31].
Dorsal and ventral striatal dopamine D1 and D2 receptors differentially. . .
J Sala-Bayo et al.
738
Neuropsychopharmacology (2020) 45:736 – 744
to collect after infusions of Raclopride (F6, 469.120= 3.511, p=
0.002), and both in latencies to collect and to respond with
administration of SCH23390 (F3, 221.033= 19.275, p < 0.001;
F3, 220.847= 24.379, p < 0.001, respectively).
Effects of D1R and D2R antagonism in the ventral striatum. Since
the three-way interactions were significant, separate multilevel
models were used to ascertain the phase-dependency of the drug
effects in each region separately. Thus, in the NAcC there was a
Dose × Phase interaction on the number of errors after raclopride
infusions (F4, 126.01= 3.905, p= 0.005). Post hoc analysis revealed
that raclopride selectively improved performance during the early
phase of reversal learning when infused in the NAcC at 0.1 μg/μl
and 1 μg/μl, compared to vehicle control (p < 0.001 and p= 0.028,
respectively; Fig. 2b). In the NAcS, there was also a Dose × Phase
interaction for errors (F4, 63.005 = 3.813, p= 0.008), but pairwise
comparisons revealed that no dose differed from the vehicle-
control group (ns). There was thus no clear effect of raclopride
when infused into the NAcS (Fig. 2e).
In contrast, analysis on the number of errors committed after
SCH23390 infusions identified a significant Dose × Phase
interaction after NAcS infusions (F2, 31.997= 25.616, p < 0.001).
Post hoc analyses showed that D1R antagonism into the NAcS
selectively decreased perseveration in the early phase compared
with the vehicle condition (p < 0.001; Fig. 2f). No main effect of
Dose or a Dose × Phase interaction was observed after SCH23390
infusions into the NAcC (ns; Fig. 2c).
The above results on the number of errors committed after
infusions into the NAcC and NAcS were similar when trials were
analyzed instead. Specifically, the interactions Dose × Phase were
significant for raclopride in the NAcC (F4, 126= 3.402, p= 0.011);
and for SCH23390 in the NAcS (F2, 32= 20.328, p < 0.001) but not
the NAcC (ns).
Table 2B shows that in the NAcC, SCH23390 strongly affected
the number of omissions (Dose × Phase: F2, 58.492= 11.838, p <
0.001). Post hoc analysis showed that SCH23390 selectively
increased the number of omissions in the early phase (p <
0.001), with no significant effect during the mid or late phases
(ns). No such effect was detected after NAcS infusions of
SCH23390, or after raclopride infusions into either the NAcC or
the NAcS (Table 2). SCH23390 infusions also prolonged the
latencies to collect the reward and to respond to the stimuli in
both sub-regions regardless of the phase (Dose: in Collect, NAcC:
F1, 57.096= 85.205, p < 0.001, and NAcS: F1, 31.062= 99.382, p <
0.001; in Respond, NAcC: F1, 57.181= 64.593, p < 0.001, and NAcS:
F1, 31.082= 7.838, p= 0.009). Raclopride had no effect on these
variables in either NAcC or NAcS (Table 2A).
Effects of D1R and D2R antagonism in the dorsal striatum. The
potential effects of drug infusions into the dorsal striatum were
analysed next. There was a phase-dependent effect of raclopride
in the DMS (Dose × Phase: F4, 196.002= 3.574, p= 0.008). As can be
seen in Fig. 3b, post hoc analysis showed that, in this region, the
high dose (1.0 µg/µl) of raclopride marginally induced a significant
Fig. 2 In the ventral striatum, reversal learning was modulated via D1R in the NAcC and D2R in the NAcS during early stages of reversal
learning. a, d Injector tip placements. Closed circles represent rats that received both raclopride and SCH23390; open circles represent rats
that received only raclopride. b, e Errors to criterion by phase—early, mid and late—after the D2R antagonist, raclopride, in the NAcC and
NAcS, respectively. c, f Errors to criterion by phase—early, mid and late—after the D1R antagonist, SCH23390, in the NAcC and NAcS,
respectively. Errors until reaching criterion of a high performance (>24/30 correct responses) are collapsed over reversals. Data shown as
mean ± SEM. *p < 0.05. ***p < 0.001.
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impairment in the mid phase (p= 0.050) versus saline. There was
no significant Dose × Phase interaction after raclopride infusions
into the DLS (ns), although a main effect of Dose and Phase was
observed (Phase: F2, 12.057= 17.472, p < 0.001; Dose: F2, 70.008=
3.764, p= 0.028). We explored this further and identified the main
effect was driven by the low dose of raclopride across all the
phases of reversal learning (Fig. 3e). D1R antagonism with
SCH23390 in the dorsal striatum did not alter performance either
in the DMS or in the DLS (Fig. 3). In all cases, the effects were
similar for trials to criterion.
Both SCH23390 and raclopride infusions increased latencies to
collect the reward across all phases when infused into the
DMS (Dose: SCH23390, F1, 113.493= 33.828, p < 0.001; Raclopride,
F2, 192.771= 14.706, p < 0.001), but not the DLS (ns). Further
analysis showed that raclopride caused this effect at both the low
and high doses (p= 0.002; p < 0.001, respectively). Omissions or
latencies to respond to the stimuli were not affected after
manipulation in any region of the dorsal striatum, neither by
raclopride nor by SCH23390 infusions (Table 2).
DISCUSSION
This study demonstrates dissociable effects on visual serial
reversal learning of D2R and D1R antagonists locally infused into
the striatum, and shows that the effects of each drug differ
fundamentally based on the striatal sub-region targeted and the
different learning phases of the task (i.e. the early, perseverative
phase versus new learning phases). An important overall finding
was that whereas DA receptor antagonism improved reversal-
learning performance in the ventral striatum, learning was
impaired after drug infusions into the dorsal striatum, clearly
showing the different roles of DA signaling within these structures
when stimulus-reward contingencies change. This finding is in
general consistent with previous data on humans with PD [32, 33]
indicating that excess DA activity may often be detrimental for
reversal performance in the NAc, whereas intact DA function in
the dorsal striatum is necessary for efficient reversal learning, as
supported by data from non-human primates [11, 34].
The effects of DA receptor blockade were highly dependent on
the phases of reversal learning, as defined by binomial distribution
probabilities (cf. [31]) to indicate whether the rats were still being
guided by the previous and obsolete stimulus-reward contingen-
cies (significant bias to the previously correct stimulus; early
phase; perseveration), at random performance (no bias; mid
phase), or had learned to respond in accordance with the new
contingencies (significant bias towards the new correct stimulus;
late phase). These phases were previously linked to defined brain
circuits; e.g., inactivation of the lateral orbitofrontal cortex (OFC)
Fig. 3 In the dorsal striatum, reversal learning was modulated via D2R in the DMS during the intermediate phase, and in the DLS during
across all the phases of reversal learning. a, d Injector tip placements. Closed circles represent rats that received both raclopride and
SCH23390; open circles represent rats that received only raclopride. b, e Errors to criterion by phase—early, mid and late—after the D2R
antagonist, raclopride, in the DMS and DLS, respectively. c, f errors to criterion by phase—early, mid and late—after the D1R antagonist,
SCH23390, in the DMS and DLS, respectively. Errors until reaching criterion of a high performance (>24/30 correct responses) are collapsed
over reversals. Data shown as mean ± SEM. #p= 0.05. *p < 0.05.
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produces increased perseveration in the early phase of visual
reversal learning in both marmoset monkeys [35] and rats [36, 37],
whereas inactivation of the medial OFC decreases perseveration in
visual reversal learning without affecting the later phases of
reversal ([37]; but see [38]). In contrast, disrupted function in the
medial prefrontal cortex of mice improves the later phases of
reversal learning [16], and excitotoxic lesions of the infralimbic
cortex impairs late learning in rats [36]. Since the above
mentioned prefrontal cortical regions form distinct circuitries
and innervate dissociable terminal fields in the striatum [39], it is
not unexpected that striatal sub-regions also mediate specific
phases of visual reversal learning, both in the present work and
from previous reports [12, 40].
The improvements in reversal learning after NAc infusions
depended on both the accumbal sub-region and the sub-type of
DA receptor, and they were selective for the early phase of
reversal learning. Whereas D1R antagonism in the NAcS decreased
perseverative errors, this effect was only observed after D2R
antagonism in the NAcC. Such a double dissociation refines
previous reports showing e.g. that elevated dopaminergic states in
the NAc are detrimental for reversal learning [18], and that D2R
agonism in the NAc impairs behavioral flexibility [17, 41]. This
could be relevant for the DA overdose hypothesis of iatrogenic
cognitive impairments associated with dopaminergic drug treat-
ment in PD [42], as our data suggest that such effects are driven
by D1R in the NAcS and D2R in the NAcC. However, since the
antagonists given here only block endogenous ligands (i.e. DA),
our data also suggest that DA signalling at D1R in the NAcS and
D2R in the NAcC contribute to perseverative responding in visual
reversal learning, perhaps by inappropriately maintaining the
previous stimulus-reward association [43] or Pavlovian condi-
tioned approach [44]. Inactivation of the NAcS can also improve
various forms of behavioral flexibility, including latent inhibition
[45], attentional set-shifting [26] and spatial reversal learning
[22, 23, 46]; our results suggest that such effects could be
mediated by D1R-expressing neurons.
Additionally, blocking D1R in the NAcC disrupted performance
overall by increasing omissions. This effect is similar to what was
previously reported after NAcC infusions of higher doses of both
raclopride and SCH23390 in rats trained on a visual reversal task
[47]. However, it is noteworthy that rats treated with intra-NAcC
SCH23390 in our task consistently initiated trials but then failed to
respond to either stimulus; again an effect only noticeable in the
early phase. While it is possible that D1R antagonism interferes
with the processing of visual cues, an alternative interpretation is
therefore that such receptor blockade selectively impairs learning
from positive feedback by blunting the impact of positive
prediction errors, as theorised by Frank and colleagues [48].
Hence, rats in our task could rapidly learn (from negative
feedback) that the previously positive stimulus is now incorrect,
but, due to the NAcC D1R blockade, not be able to update the
value they associate with the previously incorrect, now rewarded
stimulus. We recently found some evidence for such an effect of
systemic D1R antagonism in visual reversal learning [49].
In the dorsal striatum, D2R antagonism was active in the DMS
where it delayed the re-learning of the new stimulus-reward
Table 2. D1R antagonism increased omissions when infused in the NAcC.
Region Dose Omissions Latency to collect Latency to respond
Early Mid Late Early Mid Late Early Mid Late
A) Raclopride
DMS Veh 1.43 ± 0.43 1.33 ± 0.30 0.23 ± 0.12 3.06 ± 0.03 3.04 ± 0.05 2.91 ± 0.03 3.00 ± 0.02 3.00 ± 0.02 3.01 ± 0.02
0.1 1.00 ± 0.39 1.20 ± 0.37 0.43 ± 0.18 3.12 ± 0.05a 3.08 ± 0.04a 2.95 ± 0.03a 3.00 ± 0.02 3.00 ± 0.02 3.00 ± 0.02
1 2.63 ± 0.83 2.83 ± 0.74 0.63 ± 0.22 3.23 ± 0.05b 3.10 ± 0.03b 3.01 ± 0.04b 3.07 ± 0.02 3.04 ± 0.02 3.06 ± 0.02
DLS Veh 0.60 ± 0.40 0.30 ± 0.21 0.50 ± 0.50 3.01 ± 0.04 2.93 ± 0.04 3.01 ± 0.09 3.02 ± 0.07 2.98 ± 0.02 2.99 ± 0.04
0.1 0.50 ± 0.50 0.40 ± 0.13 0.10 ± 0 13 3.01 ± 0.06 2.96 ± 0.06 2.89 ± 0.07 2.99 ± 0.02 2.98 ± 0.02 2.96 ± 0.02
1 0.90 ± 0.50 0.20 ± 0.13 0.20 ± 0.13 3.07 ± 0.06 3.03 ± 0.06 2.92 ± 0.07 3.04 ± 0.02 3.01 ± 0.02 2.99 ± 0.02
NAcC Veh 2.91 ± 0.88 1.14 ± 0.33 0.36 ± 0.14 3.22 ± 0.05 3.09 ± 0.03 3.08 ± 0.04 3.08 ± 0.02 3.06 ± 0.02 3.07 ± 0.02
0.1 2.05 ± 0.64 1.41 ± 0.40 0.86 ± 0.27 3.19 ± 0.06 3.09 ± 0.03 3.03 ± 0.04 3.10 ± 0.03 3.08 ± 0.02 3.09 ± 0.02
1 3.68 ± 1.09 2.59 ± 0.89 0.36 ± 0.14 3.24 ± 0.04 3.15 ± 0.04 3.08 ± 0.50 3.13 ± 0.03 3.10 ± 0.03 3.08 ± 0.02
NAcS Veh 1.00 ± 0.70 0.50 ± 027 0.10 ± 0.10 3.26 ± 0.05 3.17 ± 0.04 3.08 ± 0.05 2.98 ± 0.03 2.91 ± 0.03 2.90 ± 0.03
0.1 0.30 ± 0.15 0.20 ± 0.22 0.10 ± 0.10 3.21 ± 0.05 3.15 ± 0.04 3.03 ± 0.05 2.90 ± 0.05 2.90 ± 0.05 2.91 ± 0.04
1 0.30 ± 0.15 0.50 ± 0.22 0.10 ± 0.10 3.17 ± 0.05 3.13 ± 0.04 3.04 ± 0.05 2.97 ± 0.05 2.91 ± 0.05 2.91 ± 0.04
B) SCH23390
DMS Veh 1.20 ± 0.54 1.56 ± 0.53 0.24 ± 0.09 3.15 ± 0.03 3.08 ± 0.03 2.99 ± 0.03 3.01 ± 0.02 3.00 ± 0.02 3.01 ± 0.02
1 1.36 ± 0.55 2.00 ± 0.75 0.60 ± 0.33 3.27 ± 0.05b 3.23 ± 0.05b 3.15 ± 0.04b 3.02 ± 0.02 3.02 ± 0.02 3.04 ± 0.02
DLS Veh 0.00 ± 0.00 0.20 ± 0.20 0.00 ± 0.00 3.07 ± 0.08 3.03 ± 0.07 3.15 ± 0.09 2.99 ± 0.04 3.00 ± 0.05 2.99 ± 0.04
1 1.40 ± 1.16 0.17 ± 0.17 0.00 ± 0.00 3.19 ± 0.06 3.16 ± 0.06 3.17 ± 0.11 3.00 ± 0.04 3.00 ± 0.03 3.02 ± 0.05
NAcC Veh 0.64 ± 0.24 1.54 ± 0.71 0.69 ± 0.47 3.23 ± 0.09 3.12 ± 0.07 3.06 ± 0.06 3.04 ± 0.03 3.01 ± 0.03 3.05 ± 0.03
1 30.08 ± 10.22c 8.08 ± 2.63 1.92 ± 0.74 3.79 ± 0.07b 3.57 ± 0.07b 3.54 ± 0.10b 3.23 ± 0.04b 3.22 ± 0.05b 3.25 ± 0.03b
NAcS Veh 0.13 ± 0.13 0.50 ± 0.38 0.00 ± 0.00 3.09 ± 0.04 3.05 ± 0.04 3.00 ± 0.05 2.99 ± 0.04 2.97 ± 0.04 2.97 ± 0.05
1 0.00 ± 0.00 1.00 ± 0.42 0.88 ± 0.30 3.47 ± 0.07b 3.34 ± 0.06b 3.32 ± 0.06b 3.01 ± 0.04b 3.01 ± 0.04b 3.07 ± 0.04b
Effects of microinfusions of the A) D2R antagonist, raclopride (0, 0.1, 1 µg/µl) and B) D1R antagonist, SCH23390 (0, 1 µg/µl), in the DMS, DLS, NAcC and NAcS
during the different phases of visual reversal learning (early, mid and late) as omissions, latencies to collect the reward and latencies to respond. Data are
mean ± SEM. Latencies are presented as log-transformed values
ap < 0.01 vs vehicle treatment, Tukey post hoc after significant Dose × Region interaction
bp < 0.001 vs vehicle treatment, Tukey post hoc after significant Dose × Region interaction
cp < 0.001 after significant Dose × Phase × Region interaction
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contingencies (mid phase), but did not affect either early or late
phases; in the DLS, D2R antagonism impaired reversal learning
overall, including the initial (perseverative) phase and during
subsequent learning. D1R antagonism showed a lack of effect in
both the DMS and the DLS at doses and infusion parameters
routinely used in the literature [50]. Hence, D2R antagonism in the
DMS and DLS had almost complementary effects with regard to
the phase of reversal that was affected. It is plausible theoretically
to reconcile this dissociation with evidence that the DMS and DLS
mediate different aspects of instrumental learning in both rodents
and humans [15]. Whereas the DMS is generally associated with
goal-directed behavior, the DLS is thought to mediate habitual,
stimulus-response behavior [13]. In this context, it is noteworthy
that well-trained visual discrimination may exhibit rule-like or
habitual tendencies [51], which need surmounting for reversal
learning to proceed. Such top-down executive control over
habitual tendencies may implicate cortico-striatal projections.
The present data suggest that striatal D2R might play an
important modulatory role in controlling habits. These findings
for the rat DLS are consistent with recent evidence that the
putamen in primates also plays a key role in reversal learning
[10, 11]. By contrast, the DMS is implicated in DA-dependent goal-
directed behavior and so the modulation of the mid phase,
characterised by new learning, by intra-DMS raclopride was
predictable. Our data on dorsal-striatal D2R and reversal learning
is in accordance with the positive relationship between behavioral
flexibility and D2R availability in both caudate and putamen, but
not ventral striatum, of vervet monkeys trained in a visual reversal
task [11]. This could be relevant also for human conditions such as
OCD and substance-use disorder, where reduced D2R binding has
been reported [52, 53]. For example, the mixed full/partial D2R
agonist pramipexole ameliorated deficits in reversal performance
in chronic stimulant abusers with a concomitant normalisation of
on-task activation of the caudate nucleus [4].
These findings add to considerable data implicating DA
receptors in reversal learning across species by showing that
D1R and D2R antagonism can both impair and improve reversal
according to the region of the striatum and at the stage of
learning this occurs. Of particular interest are two recent studies;
Horst and colleagues found that a D2R agonist infused into the
caudate nucleus improved serial visual reversal learning at
intermediate doses in marmoset monkeys [54], whereas Verharen
et al. reported that D1R and D2R agonists impaired probabilistic
spatial reversal learning in rats, both after systemic treatment and
after local infusions into the ventral striatum [41].
Limitations
A number of limitations should be borne in mind when
interpreting the results from this set of experiments. Firstly, all
rats first completed the Latin Square-design experiment investi-
gating the impact of raclopride on reversal learning, and then
received the SCH23390 infusions in a cross-over experiment. It is
possible that the additional training (three reversals minimum),
number of prior infusion events (average 12 infusions during the
raclopride experiment) or plastic changes in, e.g., membrane
presentation of receptors after exposure to a D2R antagonist
altered the impact of subsequent SCH23390 infusions. Next, all
rats in this study were male, and it is conceivable that future
studies will reveal sex differences in the impact of D2R or D1R
antagonism on reversal learning. In addition, it must be noted that
SCH23390, although frequently used for experiments targeting
the D1R, also shows affinity (as an agonist) at the serotonin 5-HT2C
receptor [55], which could in theory contribute to the effects
observed after NAcC and NAcS infusions. However, previous
reports have suggested no impact on reversal learning after 5-
HT2C receptor manipulation in the NAcC [56].
Perhaps more importantly, the D2R antagonist drug employed
also has strong dopamine D3 receptors (D3R) antagonism
properties and, so like many studies employing such drugs we
are unable clearly to distinguish between D2R and D3R actions.
Furthermore, understanding and dissecting the role of DA
signalling is challenging due to the expression of D2R both in
pre- and post-synaptic striatal neurons, as well as on striatal
GABAergic and cholinergic interneurons [57, 58].
In addition, although the present findings imply that visual
reversal learning involves sequential processing in ventral striatal
and dorsal striatal domains, more direct evidence would come
from monitoring the involvement of all of these regions
simultaneously during the course of reversal learning [12].
CONCLUSIONS
The current study elucidates the involvement of DA in reversal
learning and suggests that striatal regions differentially modulate
this form of behavioral flexibility. Using a serial visual reversal
learning task in touchscreen operant chambers, we show that
infusions of D1R and D2R antagonists in four striatal sub-regions
(NAcC, NAcS, DMS, and DLS) differentially affect distinct phases in
reversal learning. These results enhance our understanding of the
neural circuits underlying visual reversal learning and could be
relevant for cognitive inflexibility in DA-related disorders, such as
PD [32], OCD [52] or drug addiction [53].
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